PriceTargets.com logo

NeuroOne Medical Technologies - NMTC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.20
  • Forecasted Upside: 92.98%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.14 As of 04/23/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for NMTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroOne Medical Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMTC

Analyst Price Target is $2.20
▲ +92.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NeuroOne Medical Technologies in the last 3 months. The average price target is $2.20, with a high forecast of $2.20 and a low forecast of $2.20. The average price target represents a 92.98% upside from the last price of $1.14.

This chart shows the closing price for NMTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in NeuroOne Medical Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2023Alliance Global PartnersLower TargetBuy ➝ Buy$3.25 ➝ $2.20Low
3/29/2022Alliance Global PartnersLower Target$5.75 ➝ $3.25Medium
3/28/2022Craig HallumDowngradeBuy ➝ Hold$6.00 ➝ $2.00High
12/3/2021Alliance Global PartnersInitiated CoverageBuy$5.75High
11/15/2021Craig HallumInitiated CoverageBuy$6.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

NeuroOne Medical Technologies logo
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Read More

Today's Range

Now: $1.14
Low: $1.12
High: $1.14

50 Day Range

MA: $1.17
Low: $1.03
High: $1.41

52 Week Range

Now: $1.14
Low: $0.85
High: $2.00

Volume

52,236 shs

Average Volume

253,485 shs

Market Capitalization

$29.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroOne Medical Technologies?

The following Wall Street analysts have issued reports on NeuroOne Medical Technologies in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for NMTC.

What is the current price target for NeuroOne Medical Technologies?

1 Wall Street analysts have set twelve-month price targets for NeuroOne Medical Technologies in the last year. Their average twelve-month price target is $2.20, suggesting a possible upside of 93.0%. Alliance Global Partners has the highest price target set, predicting NMTC will reach $2.20 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.20 for NeuroOne Medical Technologies in the next year.
View the latest price targets for NMTC.

What is the current consensus analyst rating for NeuroOne Medical Technologies?

NeuroOne Medical Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NMTC will outperform the market and that investors should add to their positions of NeuroOne Medical Technologies.
View the latest ratings for NMTC.

What other companies compete with NeuroOne Medical Technologies?

Other companies that are similar to NeuroOne Medical Technologies include Femasys, Spectral AI, SeaStar Medical, Modular Medical and Lucid Diagnostics. Learn More about companies similar to NeuroOne Medical Technologies.

How do I contact NeuroOne Medical Technologies' investor relations team?

NeuroOne Medical Technologies' physical mailing address is 10006 Liatris Ln, EDEN PRAIRIE, MN 55347-1210, United States. The company's listed phone number is (952) 426-1383 and its investor relations email address is [email protected]. The official website for NeuroOne Medical Technologies is www.originalsourcemusic.com. Learn More about contacing NeuroOne Medical Technologies investor relations.